Oxford

Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials

by Nile
April 30, 2021

Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines.

Evox has big pharma partners. Now it has $95M to bring its own drugs to the clinic

by Nile
February 21, 2021

In the past year, Evox Therapeutics has inked alliances with two big pharma companies. The Series C financing now positions the biotech to advance to the clinic with its own exosome-based therapies.

Startups see new promise in old insight about viruses to stop cancer

by Nile
February 1, 2021

Researchers have known for decades that viruses can beat back cancer. But it’s been hard to design a virus that does the trick. A new wave of startups is optimistic they have found the keys.